On the other hand, the activation of the eCB system observed in obesity-related non-alcoholic fatty liver disease and cirrhosis goes clearly along with increased levels of CB1R gene expression in the liver [35, 36], and studies in rodents revealed a direct transcriptional upregulation of the hepatic CB1R expression by endogenous cannabinoids [37, 38]. Here, CNR1 is linked to metabolic dysfunction-associated steatotic liver disease.